LONDON (dpa-AFX) - AstraZeneca Plc.(AZN.L, AZN) and Daiichi Sankyo's
(DSKYF.PK) Enhertu has been approved in the European Union as monotherapy for
the treatment of adult patients with advanced non-small cell lung cancer or
NSCLC whose tumours have an activating HER2 (ERBB2) mutation and who require
systemic therapy following platinum-based chemotherapy with or without
immunotherapy.

Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC)
being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.

The approval by the European Commission follows the positive opinion of the
Committee for Medicinal Products for Human Use and was based on DESTINY-Lung02
Phase II trial results where AstraZeneca and Daiichi Sankyo's Enhertu
demonstrated a confirmed objective response rate of 49% and median duration of
response of 16.8 months in previously treated patients.

Following European Commission approval, an amount of $75 million is due from
AstraZeneca to Daiichi Sankyo as a milestone payment for this HER2-mutant
(HER2m) NSCLC indication.

For More Such Health News, visit rttnews.com



Copyright(c) 2023 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX